TY - JOUR
T1 - Pediatric pharmacogenomics
T2 - challenges and opportunities: on behalf of the Sanford Children’s Genomic Medicine Consortium
AU - Gregornik, David
AU - Salyakina, Daria
AU - Brown, Marilyn
AU - Roiko, Samuel
AU - Ramos, Kenneth
N1 - Funding Information:
Research projects funded by SCGMC to date have focused on rapid whole genome sequencing of newborns and next generation sequencing (NGS) of pediatric tumors. SCGMC has recently provided a total of $500,000 in seed funding for projects to be completed by consortium members in calendar year 2020. With respect to PGx, SCGMC member institutions are in various stages of implementation from reactive testing of single gene/drug pairs in specialty care services to preemptive testing of pharmacogenes for general primary and specialty care. The SCGMC is now considering options for a consortium-wide implementation project for PGx.
Publisher Copyright:
© 2020, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply .
PY - 2021/2
Y1 - 2021/2
N2 - The advent of digital, electronic, and molecular technologies has allowed the study of complete genomes. Integrating this information into drug development has opened the door for pharmacogenomic (PGx) interventions in direct patient care. PGx allows clinicians to better identify drug of choice and optimize dosing regimens based on an individual’s genetic characteristics. Integrating PGx into pediatric care is a priority for the Sanford Children’s Genomic Medicine Consortium, a partnership of ten children’s hospitals across the US committed to the innovation and advancement of genomics in pediatric care. In this white paper, we review the current state of PGx research and its clinical utility in pediatrics, a largely understudied population, and make recommendations for advancing cutting-edge practice in pediatrics.
AB - The advent of digital, electronic, and molecular technologies has allowed the study of complete genomes. Integrating this information into drug development has opened the door for pharmacogenomic (PGx) interventions in direct patient care. PGx allows clinicians to better identify drug of choice and optimize dosing regimens based on an individual’s genetic characteristics. Integrating PGx into pediatric care is a priority for the Sanford Children’s Genomic Medicine Consortium, a partnership of ten children’s hospitals across the US committed to the innovation and advancement of genomics in pediatric care. In this white paper, we review the current state of PGx research and its clinical utility in pediatrics, a largely understudied population, and make recommendations for advancing cutting-edge practice in pediatrics.
UR - http://www.scopus.com/inward/record.url?scp=85089782936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089782936&partnerID=8YFLogxK
U2 - 10.1038/s41397-020-00181-w
DO - 10.1038/s41397-020-00181-w
M3 - Review article
C2 - 32843689
AN - SCOPUS:85089782936
VL - 21
SP - 8
EP - 19
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
SN - 1470-269X
IS - 1
ER -